Prolactin (PRL) release-inhibiting properties of the alpha 2 adrenergic receptor antagonist idazoxan: comparison with yohimbine.
The effects of the alpha 2 adrenergic receptor antagonists yohimbine (YOH) and Idazoxan (ID) on secretion of PRL were compared in nonanesthetized male rats bearing permanent intraatrial cannulae for i.v. drug delivery and serial blood sampling. YOH induced a dose-related elevation of basal plasma PRL levels. ID had either no effect or a tendency to lower them and effectively inhibited stimulation of PRL secretion with morphine, 5-hydroxytryptophan (5HTP), quipazine or restraint stress. YOH at low doses did not alter the PRL secretory responses to these stimuli or enhanced them at the highest dose used (1.56 mg/kg). ID inhibited the PRL-stimulating, effect of 5HTP or morphine following inhibition of NE synthesis with FLA63 or pretreatment with clonidine. It also blocked the effect of quipazine in rats pretreated with prazosin. It is concluded that ID, in a complete contrast to YOH effectively inhibits PRL secretion. The inhibitory mechanism appears to be unrelated to its interaction with the alpha adrenergic receptors.
Krulich
L
L
Department of Physiology, University of Texas Southwestern Medical Center, Dallas 75235-9040.
Jurcovicová
J
J
Le
T
T
D006916:5-Hydroxytryptophan / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists; D000818:Animals; D005406:Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide / Q000494:pharmacology; D003000:Clonidine / Q000494:pharmacology; D004146:Dioxanes / Q000008:administration & dosage / Q000494:pharmacology*; D004147:Dioxins / Q000494:pharmacology*; D013006:Growth Hormone / Q000378:metabolism; D019329:Idazoxan; D007700:Kinetics; D008297:Male; D009020:Morphine / Q000494:pharmacology; D009638:Norepinephrine / Q000096:biosynthesis; D011224:Prazosin / Q000494:pharmacology; D011388:Prolactin / Q000378:metabolism*; D011814:Quipazine / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000502:physiology*; D012149:Restraint, Physical; D015016:Yohimbine / Q000008:administration & dosage / Q000494:pharmacology*
D000317:Adrenergic alpha-Antagonists; D004146:Dioxanes; D004147:Dioxins; D011942:Receptors, Adrenergic, alpha; D005406:Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; D015016:Yohimbine; D011814:Quipazine; D009020:Morphine; D011388:Prolactin; D013006:Growth Hormone; D006916:5-Hydroxytryptophan; D003000:Clonidine; D009638:Norepinephrine; D011224:Prazosin; D019329:Idazoxan